Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received app
Takeda Global Research & Development Center announced today that it has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to market ramelteon (TAK-375), its invest
Beginning in June 2004, the Medicare discount card program will provide America's seniors and disabled Medicare beneficiaries with much-needed discounts and information on their prescription drugs. The purchasing power behind the Medicare population is
Robert Rieveley, President of Biotech Holdings has announced that installation of pharmaceutic processing equipment required for Sucanon production is currently being completed. "Sucanon production i
Around half of the Viagra samples purchased on the Internet were counterfeit, according to researchers who are today announcing a new technique that detects counterfeit medicines at the British Pharmaceutical Conference.According to Dr Nic Wils
An alternative to mammalian gelatin for use in pharmaceutical soft capsules has been discovered by researchers at the School of Pharmacy and Chemistry at Liverpool John Moores University. The
Chiron Corporation announced that president and chief executive officer Howard Pien will appear before the U.S. Senate Special Committee on Aging in Washington, D.C., today in a hearing titled, "Combat
The AIDS Healthcare Foundation (AHF) has praised Governor Schwarzenegger for signing AB 1367 (Darrell Steinberg, D, Sacramento John Laird, D, Santa Cruz). The bill creates a pilot project for up to
Biomira and Merck KGaA have announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track status to the investigation of BLP25 Li
ID Biomedical announced today that it has been awarded a US$9.5 million grant from the U.S. National Institutes of Health (NIH) to develop its cell culture-based influenza vaccine.ID Biom
Date: Tuesday, 6-Feb-2007
Ranbaxy Laboratories announced today that the Company and GlaxoSmithKline have signed a new, multiyear R&D agreement that modifies and expands the terms of their strategic alliance established in 2003 to provide Ranbaxy expanded drug-development responsibilities and further financial opportunities.Under the original agreement, Ranbaxy conducted the optimization chemistry required to progress drug leads to the stage of candidate selection. Under the new agreement, Ranbaxy will advance leads beyond candidate selection to completion of clinical proof of concept. GSK thereafter will conduct further clinical development for each program and take resulting products through the regulatory approval process to final commercialization. Ranbaxy could receive over $100 Mn in potential milestone payments for a product developed by Ranbaxy and subsequently launched by GSK in multiple indications and up to double digit royalties on worldwide net sales. Ranbaxy will retain the right to co-commercialize the products in India. The new milestones and royalties will apply both to future drug discovery programs and to the two programs currently ongoing at Ranbaxy, that were commenced under the original agreement with GSK.
This expanded alliance envisages potential work in a wide range of therapeutics of interest to GSK, including anti-infectives and metabolic, respiratory and oncology products. While recognizing the performance and clinical-development capabilities of Ranbaxy, it also conforms to the strategy of GSK's Center of Excellence for External Drug Discovery ("CEEDD").
The CEEDD, created after the initial agreement between Ranbaxy and GSK, is a small, dedicated team that contributes to the GSK pipeline solely through the efforts of its external alliances. The CEEDD effectively 'virtualizes' a portion of the GSK pipeline; namely, from target to clinical proof of concept, by forming multiple risk-sharing/reward-sharing alliances.
Welcoming the expanded agreement with GSK, Malvinder Mohan Singh, CEO and MD, Ranbaxy, said, "This is a great moment for our scientists. The agreement presents a unique opportunity to demonstrate the India-centric advantages of high quality research and development to deliver value at the cutting edge. I believe the arrangement with GSK is path-breaking and acknowledges the higher level of R&D maturity prevalent today in our state-of-the art labs in India."
Endorsing the development, Maxine Gowen, Senior Vice President, Center of Excellence for External Drug Discovery (CEEDD), GSK, said, "This expanded agreement builds on the success of the existing collaboration and furthers our CEEDD strategy of building a strong pipeline through to clinical Proof of Concept via external R&D collaborations."
Reflecting on the agreement, Dr Pradip Bhatnagar, Vice President, New Drug Discovery Research, Ranbaxy, said, "This is a win-win agreement for both companies. By collaborating with Ranbaxy's talented R&D team, GSK will be able to develop more products for patients faster, and Ranbaxy will benefit from GSK's vast drug discovery and development experience."
http://www.ranbaxy.com/